The most optimal method of attaining therapeutic vancomycin concentrations during continuous venovenous haemofiltration (CVVH) remains unclear. Studies have shown continuous infusion vancomycin (CIV) achieves target concentrations more rapidly and consistently when compared with intermittent infusion. Positive correlations between CVVH intensity and vancomycin clearance (CL vanc ) have been noted. This study is the first to evaluate a CIV regimen in patients undergoing CVVH that incorporates weight-based CVVH intensity (mL/kg/h) into the dosing nomogram.
Introduction
Vancomycin is a tricyclic glycopeptide antibiotic with activity against a wide array of Gram-positive bacteria. The clinical effectiveness of vancomycin is believed to correlate with the 24 h area under the concentration-time curve (AUC 24 ) to the MIC ratio. 1 Trough concentrations of 10-20 mg/L have traditionally been targeted as a surrogate marker for obtaining an AUC 24 /MIC ratio !400. Unfortunately, a trough only provides information regarding the concentration at one specific point in time and may not be a true measure of AUC 24 . 2, 3 Additionally, several factors contribute to pharmacokinetic alterations in critically ill patients, further complicating dosing and monitoring strategies. Examples include modified drug metabolism and/or elimination, altered volume of distribution and use of continuous renal replacement therapy (CRRT). 4 In critically ill patients undergoing CRRT, there is no formal consensus regarding optimal dosing and monitoring of vancomycin. Anecdotally, vancomycin is dosed intermittently in this setting and adjusted based on the interpretation of frequent serum concentrations. 5 However, this approach does not consider vancomycin clearance (CL vanc ) while on CRRT, allow for estimation of AUC 24 or account for pharmacokinetic alterations caused by different CRRT modes and intensities. [6] [7] [8] [9] [10] Furthermore, a substantial portion of patients undergoing CRRT do not achieve therapeutic concentrations within 24 h and they do not consistently maintain them within the desired range. [11] [12] [13] [14] [15] Reports in the literature inidicate that continuous infusion vancomycin (CIV) achieves therapeutic targets more rapidly and consistently compared with intermittent infusion in patients with preserved renal function. Recent studies have also investigated CIV in patients undergoing CRRT. [16] [17] [18] [19] Investigators proposed a positive relationship between CRRT intensity (mL/kg/h) and CL vanc . [16] [17] [18] However, none of the previous studies utilized a standardized CIV dosing nomogram that accounted for the CRRT intensity.
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The objective of this study was to prospectively evaluate a new CIV dosing nomogram in critically ill patients undergoing continuous venovenous haemofiltration (CVVH). The nomogram determines the daily CIV dose by incorporating the weight-based CVVH intensity (mL/kg/h).
Methods
This was a prospective observational study performed at a tertiary-care academic medical centre. Institutional review board approval was obtained and the need for informed consent was waived because CIV is considered a standard of care in two ICUs: a 20 bed surgical/trauma ICU and an 18 bed mixed medical/surgical ICU.
The dosing nomogram was developed based on a previously published retrospective cohort study of critically ill patients undergoing CVVH who had received CIV at our institution. 16 Based on the correlation of CL vanc and the CVVH flow rate, the following equations were generated to develop a dosing nomogram specifically for this population: Evaluation of the new dosing nomogram was undertaken prospectively. All critically ill adults undergoing CVVH due to acute or chronic renal failure with minimal or no urine output who received CIV were included in the analyses. Patients were excluded from the analyses if their urine output was .0.5 mL/kg/h while undergoing CVVH as this may affect CL vanc , if they were concomitantly on extracorporeal membrane oxygenation or if a vancomycin serum concentration was not drawn 24 h after CIV initiation.
Patients not already receiving vancomycin therapy prior to the start of CVVH were given a 25 mg/kg loading dose followed immediately by CIV. The CIV dose was based on the CVVH flow rate divided by the actual body weight, otherwise known as the CVVH intensity (mL/kg/h). The dosing nomogram allowed patients already receiving intermittent infusion vancomycin to be converted to CIV. See Figure 1 for nomogram details.
The primary efficacy outcome was achievement of a therapeutic vancomycin concentration (15-25 mg/L) at 24 h after initiation of CIV. [20] [21] [22] [23] The secondary efficacy outcome was achievement of therapeutic concentrations at 48 and 72 h. Safety outcomes included incidences of supratherapeutic concentrations (.25 mg/L) and reports of infusion reactions and ototoxicity. An a priori-determined subgroup analysis of patients receiving a CVVH intensity .20 mL/kg/h versus ,20 mL/kg/h was performed to analyse outcomes.
Descriptive statistics were employed for all variables. v 2 or Fisher's exact test was used for categorical data, Student's t-test was used for normally distributed data and the Mann-Whitney U-test was used for nonparametric distributions. A P value ,0.05 was considered statistically significant. All analyses were performed using STATA Data Analysis and Statistical Software (version 13, StatCorp LP, College Station, TX, USA). Sin et al.
Results
During the prospective study period between November 2014 and January 2017, 71 critically ill patients undergoing CVVH received CIV and 52 were included in the analyses ( Figure S1 , available as Supplementary data at JAC Online). The majority were already receiving vancomycin therapy prior to initiation of CVVH and were subsequently switched from intermittent infusion to CIV. Patient demographics are outlined in Table S1 . Ten patients were new starts of vancomycin and received a mean (SD) loading dose of 2125 (294.6) mg. Post-load peak concentrations were obtained for 8 patients and the mean was 32.9 (8.6) mg/L. In all 52 patients, the mean maintenance infusion dose was 1355.7 (272.7) mg on day 1, 1324.3 (311) mg on day 2 and 1267.8 (311.2) mg on day 3.
For the primary outcome, 43 patients (82.7%) achieved a therapeutic vancomycin concentration at 24 h. Of the 9 patients who did not achieve a therapeutic concentration at 24 h, 7 (13.5%) were supratherapeutic and 2 (3.8%) were subtherapeutic. The mean (SD) concentration was 20.1 (4.2) mg/L at 24 h, 20.7 (3.7) mg/L at 48 h and 21.9 (3.5) mg/L at 72 h. Additional results of CIV therapy are shown in Table 1 .
For safety outcomes, no cases of infusion reactions or ototoxicity were reported. A total of 109 vancomycin concentrations were drawn within 72 h. In total, 16/109 (14.7%) concentrations were supratherapeutic (.25 mg/L). The mean supratherapeutic concentration was 27.1 (2.6) mg/L. During the 72 h period, 18 patients (34.6%) required at least one dosage adjustment.
Patients receiving a CVVH intensity .20 mL/kg/h exhibited a higher mean CL vanc compared with a CVVH intensity ,20 mL/kg/h during the first 24 h of CIV (3.1 versus 2.6 L/h; P " 0.013). There were no differences in the achievement of therapeutic concentrations at 24 h between the two groups ( Table 2) .
Discussion
To our knowledge, this is the first study incorporating CVVH intensity into a CIV dosing nomogram. Based on the results, the majority of patients achieved a therapeutic vancomycin serum concentration at 24 h and no notable adverse events were reported.
Therapeutic concentrations were generally maintained at 48 and 72 h. The mean vancomycin concentrations at 48 and 72 h were slightly higher than at 24 h. This may have been the result of several patient-specific factors including drug accumulation, lower volume of distribution due to extracorporeal fluid removal, approaching steady-state concentrations and/or other pharmacokinetic modifications in critical illness. The rapid changes in clinical conditions and pharmacokinetic parameters of critically ill patients undergoing CRRT may warrant the implementation of more frequent therapeutic drug monitoring. Serum concentrations of vancomycin should be closely monitored to avoid therapeutic failures, curb emergence of antimicrobial resistance and minimize potential toxicities.
Various CIV regimens have previously been studied and noted positive correlations between CRRT intensity and CL vanc . [16] [17] [18] The CIV dosing nomogram herein incorporates CVVH intensity in an attempt to provide more individualized regimens based on the predicted CL vanc . This nomogram is unique with respect to the following aspects: patients with a higher CVVH flow rate will receive a larger CIV dose and an inverse relationship has been designated between actual body weight and the CIV dose. Since the CVVH intensity is weight-based (mL/kg/h), the intensity will be higher in patients with a lower actual body weight at the same CVVH flow rate. As shown in Table 2 , CL vanc is significantly higher in patients who received a greater weight-based CVVH intensity, despite the mean crude non-weight-based CVVH flow rate being similar between the two groups.
Administering CIV is an example of AUC-driven therapy. Traditional trough-driven therapy with intermittent infusion may underestimate the true AUC 24 , as it does not account for the variability in peak and trough concentrations. 2, 3 In contrast, CIV appears to allow for a more accurate estimation of AUC 24 . It may minimize high peak concentrations and create a more predictable serum concentration-time profile. 24, 25 Once steady-state has been achieved with CIV, AUC 24 can be calculated as follows: All results are expressed as mean (SD) or n (%). a Post-load peak concentrations were drawn 1 h after the loading dose was finished infusing. This equation assumes the CVVH circuit has been running constantly and vancomycin is being cleared continuously. To account for instances when the circuit becomes clotted or is shut down, the nurse temporarily holds the vancomycin infusion since we are assuming the patient has minimal intrinsic clearance. The infusion is then resumed by the nurse when the CVVH circuit is restarted. This is of importance in certain patients undergoing CVVH for whom renal recovery may be expected, as minimizing their vancomycin exposure is essential, while still maintaining an adequate AUC 24 . With intermittent infusion, if a patient receives a full vancomycin dose and the CVVH circuit subsequently clots or is stopped, the lack of CL vanc may result in high drug exposure and a markedly elevated AUC 24 . In our study population, patients may have experienced some renal recovery during the period when they were undergoing CVVH and receiving CIV, which would theoretically increase CL vanc and lower serum concentrations of vancomycin. A timed 24 h urine collection for creatinine clearance (CL CR ), obtained while on CRRT, may help capture the additional intrinsic clearance of vancomycin and assess the recovery of renal function after acute injury. At our institution, a 24 h urine CL CR was not considered a standard of practice in our critical care units, but may be a focus of future studies as it has the potential to add valuable information on drug clearance. Daily vancomycin requirements via continuous infusion have been shown to correlate with a timed urine CL CR . [26] [27] [28] [29] However, these studies excluded patients with renal failure undergoing CRRT; thus, the utility of a timed urine CL CR in this specific patient population requires further investigation. Augmented renal clearance (ARC) has been identified as a common phenomenon in the critically ill. 30 ARC is an aspect that should not be underestimated since it may be associated with suboptimal pharmacotherapy, including subtherapeutic serum concentrations of vancomycin during CIV. 27, 28, 31 Of note, our current study only included patients with acute or chronic renal failure undergoing CVVH. Therefore, ARC was likely not observed in our population. Future investigations of ARC in the intensive care setting are also needed to determine optimal dosing regimens.
Several limitations of the current study have been identified. First, the study only evaluates CIV within the first 72 h of initiation. As patients progress through their treatment, they may exhibit further pharmacokinetic modifications, thereby causing potentially unpredictable alterations in drug therapy. In addition, the initial body weight used for calculations may not have been fully accurate or may have fluctuated throughout the treatment course with changes in fluid and nutrition status. Second, our study cannot evaluate for non-renal clearance of vancomycin such as biliary elimination or elimination via surgical drains or negative-pressure wound therapy. The majority of patients were from the surgical critical care population and our results may not be extrapolatable to populations with different mechanisms of non-CVVH-related CL vanc . Third, limited numbers of patients received loading doses as new initiations of vancomycin therapy, which provided insufficient data to assess the adequacy of our loading dose. This is of interest given that critically ill and fluid-overloaded patients may require larger loading doses. Fourth, this study was not designed to evaluate clinical efficacy or microbiological cure with CIV. Further studies are needed to determine if optimizing concentrations via CIV during CVVH affects clinical outcomes. Fifth, although there were no reported cases of ototoxicity, routine auditory testing was not performed. Lastly, our institution used CVVH exclusively as the mode of CRRT. Therefore, these results cannot be extrapolated to patients receiving continuous venovenous haemodialysis (CVVHD) or continuous venovenous haemodiafiltration (CVVHDF), as they are expected to have different CL vanc . Despite this, other institutions may use a similar framework to develop a CIV dosing nomogram that incorporates CVVHD or CVVHDF intensity.
In conclusion, by using a CIV dosing nomogram incorporating the intensity of renal replacement therapy, the majority of critically All results are expressed as mean (SD) or n (%).
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ill patients can achieve therapeutic concentrations within 24 h and consistently maintain them within target range at 48 and 72 h. Additional studies are required to validate this nomogram before widespread implementation may be considered.
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